

Stefan MÃ¼hlebach

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11256230/publications.pdf>

Version: 2024-02-01

32
papers

4,010
citations

567281

15
h-index

377865

34
g-index

35
all docs

35
docs citations

35
times ranked

4946
citing authors

#	ARTICLE	IF	CITATIONS
1	Tackling the challenges of nanomedicines: are we ready?. American Journal of Health-System Pharmacy, 2021, 78, 1047-1056.	1.0	8
2	ESPEN practical guideline: Clinical Nutrition in cancer. Clinical Nutrition, 2021, 40, 2898-2913.	5.0	472
3	How Do Hospital Pharmacists Approach Substitution of Nanomedicines? Insights from a Qualitative Pilot Study and a Quantitative Market Research Analysis in Five European Countries. Pharmaceutics, 2021, 13, 1010.	4.5	1
4	Physicochemical Stability and Compatibility Testing of Voriconazole in All-in-One Parenteral Nutrition Admixtures. Pharmaceutics, 2021, 13, 1447.	4.5	2
5	Management of Home Parenteral Nutrition: Complications and Survival. Annals of Nutrition and Metabolism, 2021, 77, 46-55.	1.9	7
6	ESPEN guideline on home parenteral nutrition. Clinical Nutrition, 2020, 39, 1645-1666.	5.0	152
7	Pharmaceutical Aspects of Artificial Nutrition. Journal of Clinical Medicine, 2019, 8, 2017.	2.4	12
8	Nanomedicines: The magic bullets reaching their target?. European Journal of Pharmaceutical Sciences, 2019, 128, 73-80.	4.0	73
9	Diets and Diet Therapy: Parenteral Nutrition. , 2019, , 131-142.		1
10	Medication practice in hospitals: are nanosimilars evaluated and substituted correctly?. European Journal of Hospital Pharmacy, 2018, 25, 79-84.	1.1	12
11	Are patients affected by mitochondrial disorders at nutritional risk?. Nutrition, 2018, 47, 56-62.	2.4	12
12	Editorial: Drug Nanoparticles and Nano-Cocrystals: From Production and Characterization to Clinical Translation. Advanced Drug Delivery Reviews, 2018, 131, 1-2.	13.7	14
13	Regulatory challenges of nanomedicines and their follow-on versions: A generic or similar approach?. Advanced Drug Delivery Reviews, 2018, 131, 122-131.	13.7	94
14	How to select a nanosimilar. Annals of the New York Academy of Sciences, 2017, 1407, 50-62.	3.8	30
15	ESPEN guidelines on nutrition in cancer patients. Clinical Nutrition, 2017, 36, 11-48.	5.0	1,855
16	Free phenytoin assessment in patients: measured versus calculated blood serum levels. International Journal of Clinical Pharmacy, 2016, 38, 303-309.	2.1	11
17	Diluting ferric carboxymaltose in sodium chloride infusion solution (0.9% w/v) in polypropylene bottles and bags: effects on chemical stability. European Journal of Hospital Pharmacy, 2016, 23, 22-27.	1.1	4
18	Simple training tool is insufficient for appropriate diagnosis and treatment of malnutrition: A pre-post intervention study in a tertiary center. Nutrition, 2016, 32, 355-361.	2.4	13

#	ARTICLE	IF	CITATIONS
19	Is the EU ready for non-biological complex drug products?. GaBI Journal, 2016, 5, 101-102.	0.3	3
20	Management of Home Parenteral Nutrition: A Prospective Multicenter Observational Study. Annals of Nutrition and Metabolism, 2015, 67, 210-217.	1.9	14
21	Introduction: Defining the Position of Non-Biological Complex Drugs. AAPS Advances in the Pharmaceutical Sciences Series, 2015, , 1-8.	0.6	8
22	Iron Carbohydrate Complexes: Characteristics and Regulatory Challenges. AAPS Advances in the Pharmaceutical Sciences Series, 2015, , 149-170.	0.6	7
23	Regulatory challenges and approaches to characterize nanomedicines and their follow-on similars. Nanomedicine, 2015, 10, 659-674.	3.3	51
24	Non-biological complex drugs (NBCDs) and their follow-on versions: time for an editorial section. GaBI Journal, 2015, 4, 167-170.	0.3	5
25	Nanomedicines: addressing the scientific and regulatory gap. Annals of the New York Academy of Sciences, 2014, 1313, 35-56.	3.8	364
26	Different Pharmaceutical Products Need Similar Terminology. AAPS Journal, 2014, 16, 11-14.	4.4	53
27	How to Regulate Nonbiological Complex Drugs (NBCD) and Their Follow-on Versions: Points to Consider. AAPS Journal, 2014, 16, 15-21.	4.4	101
28	Workshop on the challenges in substitution of nonbiological complex drugs. American Journal of Health-System Pharmacy, 2013, 70, 1879-1880.	1.0	3
29	The authorization of non-biological complex drugs (NBCDs) follow-on versions: specific regulatory and interchangeability rules ahead?. GaBI Journal, 2013, 2, 204-207.	0.3	13
30	Nanoparticle iron medicinal products – Requirements for approval of intended copies of non-biological complex drugs (NBCD) and the importance of clinical comparative studies. Regulatory Toxicology and Pharmacology, 2012, 64, 324-328.	2.7	48
31	The therapeutic equivalence of complex drugs. Regulatory Toxicology and Pharmacology, 2011, 59, 176-183.	2.7	86
32	ESPEN Guidelines on Parenteral Nutrition: Home Parenteral Nutrition (HPN) in adult patients. Clinical Nutrition, 2009, 28, 467-479.	5.0	365